Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 32,900
-1,000 (-2.95%)
Last updated: Sep 9, 2025, 9:33 AM KST
Hanall Biopharma Revenue
Hanall Biopharma had revenue of 40.68B KRW in the quarter ending June 30, 2025, with 28.77% growth. This brings the company's revenue in the last twelve months to 150.09B, up 15.12% year-over-year. In the year 2024, Hanall Biopharma had annual revenue of 138.94B with 2.99% growth.
Revenue (ttm)
150.09B
Revenue Growth
+15.12%
P/S Ratio
11.46
Revenue / Employee
493.71M
Employees
304
Market Cap
1,720.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
| Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
| Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
| Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
| Dec 31, 2020 | 88.60B | -19.85B | -18.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Peptron | 5.18B |
| LigaChem Biosciences | 148.28B |